Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase II

MSICS Pharma

1 Drug Candidate

MSICS Pharma is an Israeli biotechnology company that operates a GMP production facility for naturally-sourced psilocybin. Their lead candidate MSX-06, a naturally-sourced psilocybin formulation, is in Phase 2 clinical development targeting treatment-resistant depression and obsessive-compulsive disorder.

Drug Pipeline

1
Phase II
Treatment-Resistant Depression (TRD)Obsessive-Compulsive Disorder (OCD)

Naturally-sourced psilocybin formulation produced in GMP-certified facility. Phase 2 for TRD and OCD.

Quick Facts

Type
Private Biotech
Lead Stage
Phase II
Website
Visit